SNGX · Soligenix, Inc.
What's happening
- SNGX is up 6.91% today, trading at $0.36. — Live quote
- Volume today (758) is well below its 3-month average of 329,440. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.12 actual vs. $-0.16 estimated (+24.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $6.7M | $396.5K | $168.0K | $141.7K | $221.2K |
| P/E | -0.66 | -0.04 | -0.02 | -0.02 | -0.03 |
| Price/Book | 1.00 | 0.13 | 0.02 | 0.08 | 0.06 |
| ROE | -151.16% | -356.29% | -130.34% | -493.02% | -211.15% |
| ROA | -95.67% | -159.03% | -87.69% | -156.53% | -106.25% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -1424.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -79.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SNGX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $2.3K | $117.0K |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.1M | -$2.9M | -$2.6M | -$2.8M | -$3.0M | -$1.9M | -$1.7M | -$2.1M |
| Net income | -$2.0M | -$2.8M | -$2.5M | -$2.7M | -$3.0M | -$1.7M | -$1.6M | -$1.9M |
| EPS (diluted) | $-0.12 | $-0.28 | $-0.58 | $-0.82 | $-0.97 | $-0.78 | $-1.31 | $-2.91 |
| EPS (basic) | $-0.12 | $-0.28 | $-0.58 | $-0.82 | $-0.97 | $-0.78 | $-1.31 | $-2.91 |
| Operating margin | — | — | — | — | — | — | -$74.5K | -$1.8K |
| Net margin | — | — | — | — | — | — | -$70.2K | -$1.6K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $10.5M | $6.9M | $9.2M | $11.3M | $5.8M | $7.7M | $9.0M | $10.5M |
| Total liabilities | $3.9M | $3.8M | $3.9M | $3.7M | $3.9M | $3.8M | $4.8M | $4.5M |
| Stockholders' equity | $6.6M | $3.1M | $5.3M | $7.6M | $1.8M | $3.9M | $4.1M | $5.9M |
| Total current assets | $10.2M | $6.6M | $8.8M | $10.9M | $5.3M | $7.6M | $8.8M | $10.3M |
| Total current liabilities | $3.7M | $3.6M | $3.7M | $3.4M | $3.6M | — | $4.8M | $4.5M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $6.6K | $7.7K | $8.8K | $7.8K | $8.1K | $5.5K | $6.1K | $7.2K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $1.4M | $828.7K | $1.1M | $1.2M | $650.0K | $599.7K | $667.9K | $891.2K |
| Accrued liabilities | $2.1M | $2.6M | $2.0M | $2.0M | $2.8M | $3.1M | $2.4M | $1.4M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | $0 | — |
| Common stock & paid-in capital | $21.6K | $10.5K | $10.1K | $9.9K | $3.5K | $3.2K | $2.5K | $2.3K |
| Retained earnings | -$249.9M | -$247.9M | -$245.1M | -$242.2M | -$239.6M | -$237.2M | -$234.0M | -$231.0M |
| Accumulated other comprehensive income (loss) | $45.8K | $45.8K | $45.8K | $45.8K | $45.8K | $45.8K | $45.8K | $37.5K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.7M | -$2.4M | -$2.7M | -$2.9M | -$2.7M | -$1.8M | -$2.2M | -$2.9M |
| Investing cash flow | — | — | -$2.0K | -$608 | -$3.3K | — | — | — |
| Financing cash flow | $5.5M | $451.0K | $157.9K | $8.4M | $545.6K | $1.3M | $242.9K | $3.3M |
| Free cash flow | — | — | -$2.7M | -$2.9M | -$2.7M | — | — | — |
| Capital expenditures | — | — | $2.0K | $608 | $3.3K | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $116.0K | $121.2K | $320.1K | $104.3K | $99.5K | $63.6K | $155.5K | $56.6K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $119.4K | $839.4K | $948.9K | $824.3K |
| Gross profit | — | — | $97.3K | $398.1K | $95.6K |
| Operating income | -$11.8M | -$9.4M | -$7.7M | -$14.2M | -$13.1M |
| Net income | -$11.1M | -$8.3M | -$6.1M | -$13.8M | -$12.6M |
| EPS (diluted) | $-2.14 | $-4.98 | $-12.66 | $-4.81 | $-4.69 |
| EPS (basic) | $-2.14 | $-4.98 | $-12.66 | $-4.81 | $-4.69 |
| Operating margin | — | -$7.9K | -$917 | -$1.5K | -$1.6K |
| Net margin | — | -$6.9K | -$732 | -$1.5K | -$1.5K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $9.2M | $9.0M | $9.8M | $14.3M | $26.9M |
| Total liabilities | $3.9M | $4.8M | $7.3M | $16.8M | $16.1M |
| Stockholders' equity | $5.3M | $4.1M | $2.5M | -$2.5M | $10.7M |
| Total current assets | $8.8M | $8.8M | $9.5M | $13.9M | $26.6M |
| Total current liabilities | $3.7M | $4.8M | $6.2M | $16.5M | $6.3M |
| Cash & equivalents | — | — | — | — | $26.0M |
| Property, plant & equipment | $8.8K | $6.1K | $11.9K | $18.5K | $22.2K |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | — | — | — | — | $7.8K |
| Accounts payable | $1.1M | $667.9K | $1.1M | $3.9M | $2.9M |
| Accrued liabilities | $2.0M | $2.4M | $2.4M | $2.3M | $3.0M |
| Long-term debt | — | $0 | $1.0M | $0 | — |
| Common stock & paid-in capital | $10.1K | $2.5K | $649 | $2.9K | $2.9K |
| Retained earnings | -$245.1M | -$234.0M | -$225.7M | -$219.6M | -$205.8M |
| Accumulated other comprehensive income (loss) | $45.8K | $45.8K | $22.2K | $24.7K | $41.9K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.3M | -$8.4M | -$8.6M | -$12.6M | -$11.7M |
| Investing cash flow | -$5.9K | — | — | -$13.1K | -$11.8K |
| Financing cash flow | $10.4M | $7.8M | $3.7M | $76.8K | $19.1M |
| Free cash flow | -$10.3M | — | — | — | — |
| Capital expenditures | $5.9K | — | — | — | — |
| Depreciation & amortization | — | — | — | — | $34.2K |
| Share-based compensation | $587.6K | $329.8K | $370.2K | $333.4K | $361.6K |
| Deferred income taxes | — | — | — | — | — |
| Change in inventory | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SNGX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-10-02 to 2025-10-02
Recent transactions
- Most recent: SCHABER CHRISTOPHER J (CHAIRMAN, CEO AND PRESIDENT) — Open market purchase of 15,132 shares on 2025-10-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | Open market purchase | 2025-10-02 | 15,132 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-10-02 | SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PRESIDENT | Open market purchase | 15,132 | $1.32 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:40 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-09-21 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-17 | View on SEC.gov → |
Recent news
Headlines about SNGX (Soligenix, Inc.). Links open the publisher — we don’t host full articles.
-
Radiotherapy-Induced Oral Mucositis Market Set for Strong Growth Through 2036, Driven by Emerging Therapies and Rising Cancer Burden | DelveInsight
Yahoo Finance · 2026-08-20 -
SNGX: Applying for Vaccine Development Funding for Ebola Vaccine
Yahoo Finance · 2026-08-12 -
Soligenix culls topical lymphoma asset after Phase III miss
Yahoo Finance · 2026-08-10 -
Soligenix GAAP EPS of -$0.12 beats by $0.10
Seeking Alpha · 2026-08-07 -
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
Yahoo Finance · 2026-08-07 -
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Yahoo Finance · 2026-06-08 -
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy
Yahoo Finance · 2026-05-27 -
SNGX Phase 3 Trial Halted on HyBryte
Yahoo Finance · 2026-04-28
No headlines in this category right now — try “All”.